Secukinumab (Cosentyx®) for Psoriatic Arthritis

Assessment Status Rapid Review Complete
Drug Secukinumab
Brand Cosentyx®
Indication Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
Assessment Process
Rapid review commissioned 02/12/2015
Rapid review completed 15/12/2015
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended

The HSE has approved reimbursement following confidential price negotiations.